鸟苷 5'-(四氢 5-硫代三磷酸酯) | 37589-80-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: 鸟苷 5'-(四氢 5-硫代三磷酸酯)
• 中文别名: 鸟苷5'-(四氢5-硫代三磷酸酯)
• 英文名称: guanosine-5'-O-(3-thiophosphate)
• 英文别名: GTPγS；guanosine 5'-O-(3-thiotriphosphate)；guanosine 5'-3-O-(thio)triphosphate；guanosine 5'-γthiotriphosphate；guanosine 5'-O-(thiotriphosphate)；[[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-sulfanylphosphinic acid
• CAS: 37589-80-3
• 化学式: C₁₀H₁₆N₅O₁₃P₃S
• 分子量: 539.25
• InChiKey: XOFLBQFBSOEHOG-UUOKFMHZSA-N

物化性质

• 密度：
  2.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  310
• 氢给体数：
  8
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  鸟苷 5'-(四氢 5-硫代三磷酸酯) 、 尿苷-5’-二磷酸 在 nucleotide diphosphate kinase 作用下， 生成 uridine 5'-O-(3-thiotriphosphate)
  参考文献：
  名称：

  Uridine nucleotide-induced stimulation of gluconeogenesis in isolated rat proximal tubules

  摘要：

  Uridine nucleotides, released into the extracellular environment, influence a variety of metabolic and other cellular activities in a wide range of target tissues. Here we have studied the effects of uridine nucleotides on gluconeogenesis in isolated rat proximal tubules. Gluconeogenesis, from a range of precursors, was stimulated following exposure of isolated proximal tubules to either UTP or UTPgammaS, but not when exposed to other uridine-containing nucleotides. UTP- and UTPgammaS-induced gluconeogenesis was diminished in the presence of purinoceptor antagonists (e.g. suramin, PPADS) indicative of a role for P2Y(2)-like purinoceptors in these effects. Likewise, agents that interfere with either phospholipase C activation or intracellular Ca2+ mobilization decreased UTP- and UTPgammaS-induced stimulation of gluconeogenesis consistent with a role for these secondary messenger systems in the mechanism of action of extracellular UTP and UTPgammaS on proximal tubule metabolism.

  DOI：

  10.1007/s00210-002-0571-9

文献信息

• POSITIVE ALLOSTERIC MODULATORS OF HUMAN MELANOCORTIN-4 RECEPTOR
  申请人：Vanderbilt University

  公开号：US20170349571A1

  公开（公告）日：2017-12-07

  Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.

  披露的是黑皮质素受体的正向别构调节剂以及使用这些调节剂的方法。
• ORVINOL AND THEVINOL DERIVATIVES USEFUL IN THE TREATMENT OF DRUG AND ALCOHOL ABUSE
  申请人：Lewis John

  公开号：US20140213603A1

  公开（公告）日：2014-07-31

  The invention provides orvinol and thevinol compounds useful for the treatment of drug and alcohol abuse, the compounds being particularly useful for the prevention of relapse in recovering addicts.

  这项发明提供了用于治疗药物和酒精滥用的奥维诺尔（orvinol）和西维诺尔（thevinol）化合物，这些化合物特别适用于预防康复成瘾者的复发。
• [EN] CB1 MODULATOR COMPOUNDS<br/>[FR] COMPOSES MODULATEURS DE CB1
  申请人：LILLY CO ELI

  公开号：WO2005066126A1

  公开（公告）日：2005-07-21

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

  结构式（I）的新化合物已被披露。作为大麻素-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面是有用的。因此，本发明的化合物在治疗、预防和抑制精神病、记忆缺陷、认知障碍、偏头痛、神经病、神经炎性疾病（例如多发性硬化症、吉兰-巴雷综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面是有用的。这些化合物还可用于治疗物质滥用障碍，特别是对阿片类药物、酒精和尼古丁的治疗。这些化合物还可用于治疗与过度食物摄入及相关并发症相关的肥胖症或进食障碍。
• KAPPA OPIOID RECEPTOR BINDING LIGANDS
  申请人：Carroll Frank Ivy

  公开号：US20130158072A1

  公开（公告）日：2013-06-20

  Kappa opioid recep-tor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor, such as heroin or cocaine addictions.

  Kappa阿片受体拮抗剂提供了在kappa阿片受体的功能结合测定中产生显著改善的结果，并且这些拮抗剂在治疗通过结合kappa阿片受体得到改善的疾病状态中的使用，比如海洛因或可卡因成瘾。
• [EN] CANNABINOID TYPE 1 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR CANNABINOÏDE DE TYPE 1
  申请人：UNIV TORONTO

  公开号：WO2016029310A1

  公开（公告）日：2016-03-03

  The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

  本公开涉及公式（I）的吲哚衍生物，这些衍生物是大麻素类型1受体调节剂，对于治疗需要调节受体的疾病是有益的；涉及它们的制备方法；包含它们的药物组合物；以及使用它们的方法。